AEMD vs EKSO vs NVCR vs IRBT

For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.

3% revenue growth year-over-year, versus -28. 6% for Ekso Bionics Holdings, Inc. (EKSO). Analysts rate Ekso Bionics Holdings, Inc. (EKSO) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Ekso Bionics Holdings, Inc.

(EKSO) delivered a total return of -84. 7%, compared to -99. 9% for iRobot Corporation (IRBT). Over 10 years, the gap is even starker: NVCR returned +38. 5% versus AEMD's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Aethlon Medical, Inc.

(AEMD) is the lower-risk stock at 1. 41β versus iRobot Corporation's 5. 31β — meaning IRBT is approximately 277% more volatile than AEMD relative to the S&P 500. On balance sheet safety, Aethlon Medical, Inc. (AEMD) carries a lower debt/equity ratio of 13% versus 4% for iRobot Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.

3% versus -28. 6% for Ekso Bionics Holdings, Inc. (EKSO). On earnings-per-share growth, the picture is similar: iRobot Corporation grew EPS 55. 3% year-over-year, compared to -776. 8% for Ekso Bionics Holdings, Inc.. Over a 3-year CAGR, NVCR leads at 6. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Aethlon Medical, Inc.

(AEMD) is the more profitable company, earning 0. 0% net margin versus -91. 4% for Ekso Bionics Holdings, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AEMD leads at 0. 0% versus -104. 1% for EKSO. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, EKSO (0.

8% yield) pays a dividend. AEMD, NVCR, IRBT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Aethlon Medical, Inc.

(AEMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. iRobot Corporation (IRBT) carries a higher beta of 5. 31 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AEMD: -100. 0%, IRBT: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AEMD (Healthcare) and EKSO (Healthcare) and NVCR (Healthcare) and IRBT (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

EKSO pays a dividend while AEMD, NVCR, IRBT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.